Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(1):99–107. doi: 10.1038/sj.bjc.6690657

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

A H Thomson 1, P A Vasey 2, L S Murray 1, J Cassidy 4, D Fraier 3, E Frigerio 3, C Twelves 2
PMCID: PMC2374352  PMID: 10487619

Abstract

Doxorubicin pharmacokinetics were determined in 33 patients with solid tumours who received intravenous doses of 20–320 mg m−2 HPMA copolymer bound doxorubicin (PK1) in a phase I study. Since assay constraints limited the data at lower doses, conventional analysis was not feasible and a ‘population approach’ was used. Bound concentrations were best described by a biexponential model and further analyses revealed a small influence of dose or weight on V1 but no identifiable effects of age, body surface area, renal or hepatic function. The final model was: clearance (Q) 0.194 l h−1; central compartment volume (V1) 4.48 × (1+0.00074 × dose (mg)) l; peripheral compartment volume (V2) 7.94 l; intercompartmental clearance 0.685 l h−1. Distribution and elimination half-lives had median estimates of 2.7 h and 49 h respectively. Free doxorubicin was present at most sampling times with concentrations around 1000 times lower than bound doxorubicin values. Data were best described using a biexponential model and the following parameters were estimated: apparent clearance 180 l h−1; apparent V1 (l) 1450 × (1+0.0013 × dose (mg)), apparent V2 (l) 21 300 × (1–0.0013 × dose (mg)) × (1+2.95 × height (m)) and apparent Q 6950 l h−1. Distribution and elimination half-lives were 0.13 h and 85 h respectively. © 1999 Cancer Research Campaign

Keywords: PK1-doxorubicin, solid tumours, population pharmacokinetics

Full Text

The Full Text of this article is available as a PDF (122.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amantea M. A., Forrest A., Northfelt D. W., Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther. 1997 Mar;61(3):301–311. doi: 10.1016/S0009-9236(97)90162-4. [DOI] [PubMed] [Google Scholar]
  2. Bruno R., Vivier N., Vergniol J. C., De Phillips S. L., Montay G., Sheiner L. B. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996 Apr;24(2):153–172. doi: 10.1007/BF02353487. [DOI] [PubMed] [Google Scholar]
  3. Chabot G. G., Abigerges D., Catimel G., Culine S., de Forni M., Extra J. M., Mahjoubi M., Hérait P., Armand J. P., Bugat R. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol. 1995 Feb;6(2):141–151. doi: 10.1093/oxfordjournals.annonc.a059109. [DOI] [PubMed] [Google Scholar]
  4. Chatelut E., Canal P., Brunner V., Chevreau C., Pujol A., Boneu A., Roché H., Houin G., Bugat R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995 Apr 19;87(8):573–580. doi: 10.1093/jnci/87.8.573. [DOI] [PubMed] [Google Scholar]
  5. Dobbs N. A., Twelves C. J., Gillies H., James C. A., Harper P. G., Rubens R. D. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 1995;36(6):473–476. doi: 10.1007/BF00685796. [DOI] [PubMed] [Google Scholar]
  6. Fraier D., Frigerio E., Pianezzola E., Strolin Benedetti M., Cassidy J., Vasey P. A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection. J Pharm Biomed Anal. 1995 Apr;13(4-5):625–633. doi: 10.1016/0731-7085(95)01301-z. [DOI] [PubMed] [Google Scholar]
  7. Jacquet J. M., Bressolle F., Galtier M., Bourrier M., Donadio D., Jourdan J., Rossi J. F. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol. 1990;27(3):219–225. doi: 10.1007/BF00685716. [DOI] [PubMed] [Google Scholar]
  8. Jodrell D. I., Reyno L. M., Sridhara R., Eisenberger M. A., Tkaczuk K. H., Zuhowski E. G., Sinibaldi V. J., Novak M. J., Egorin M. J. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol. 1994 Jan;12(1):166–175. doi: 10.1200/JCO.1994.12.1.166. [DOI] [PubMed] [Google Scholar]
  9. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986 Dec;46(12 Pt 1):6387–6392. [PubMed] [Google Scholar]
  10. Nguyen L., Chatelut E., Chevreau C., Tranchand B., Lochon I., Bachaud J. M., Pujol A., Houin G., Bugat R., Canal P. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol. 1998;41(2):125–132. doi: 10.1007/s002800050718. [DOI] [PubMed] [Google Scholar]
  11. Piscitelli S. C., Rodvold K. A., Rushing D. A., Tewksbury D. A. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther. 1993 May;53(5):555–561. doi: 10.1038/clpt.1993.69. [DOI] [PubMed] [Google Scholar]
  12. Schoemaker R. C., Cohen A. F. Estimating impossible curves using NONMEM. Br J Clin Pharmacol. 1996 Sep;42(3):283–290. doi: 10.1046/j.1365-2125.1996.04231.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sheiner L. B., Rosenberg B., Marathe V. V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977 Oct;5(5):445–479. doi: 10.1007/BF01061728. [DOI] [PubMed] [Google Scholar]
  14. Yuh L., Beal S., Davidian M., Harrison F., Hester A., Kowalski K., Vonesh E., Wolfinger R. Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. Biometrics. 1994 Jun;50(2):566–575. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES